Abstract
Preclinical studies have shown that a very low dose of naltreoxone hydrochloride (NTX), an opiate antagonist, can block excitatory opioid receptors without affecting inhibitory opioid receptors, resulting in analgesic potency without side effects. The present study assessed the efficacy and safety of PTI-901 (low-dose NTX) treatment in Irritable bowel syndrome (IBS) patients. Forty-two IBS patients participated in an open-label study. Participants received 0.5 mg PTI-901/day for 4 weeks and were evaluated during baseline, during treatment, and at 4-week follow-up. Patients recorded degree of abdominal pain, stool urgency, consistency, and frequency. Primary outcomes were number of pain-free days and overall symptom relief, evaluated by a global assessment score. Data were analyzed per protocol. Global assessment improved in 76% of 42 patients. During treatment, the mean weekly number of pain-free days increased from 0.5±1 to 1.25±2.14 (P=0.011). There were no significant adverse reactions. PTI-901 improves pain and overall feeling, and is well tolerated by IBS patients. A large, randomized, double-blind, placebo-controlled study is justified.
Similar content being viewed by others
References
Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA (1999) Functional bowel disorders and functional abdominal pain. Gut 45(Suppl 2):43–47
Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, de Wit N (2005) Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev April 18(2):CD003460
FDA (2004) New risk information on IBS drug Zelnorm. FDA Consum 38:6
Fioramonti J, Bueno L (2002) Centrally acting agents and visceral sensitivity. Gut 51(Suppl 1):i91–i95
Shen KF, Crain SM (1989) Dual opioid modulation of the action potential duration of mouse dorsal root ganglion neurons in culture. Brain Res 491:227–242
Crain SM, Shen KF (1990) Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol Sci 11:77–81
Fan SF, Shen KF, Crain SM (1991) Opioids at low concentration decrease openings of K+ channels in sensory ganglion neurons. Brain Res 558:166–170
Crain SM, Shen KF (1995) Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proc Natl Acad Sci USA 92:10540–10544
Shen KF, Crain SM (1997) Ultra-low doses of naltrexone or etorphine increase morphine's antinociceptive potency and attenuate tolerance/dependence in mice. Brain Res 757:176–190
Xu H, Smolens I, Gintzler AR (1989) Opioids can enhance and inhibit the electrically evoked release of methionine-enkephalin. Brain Res 504:36–42
Lembo T, Naliboff BD, Matin K, Munakata J, Parker RA, Gracely RH, Mayer EA (2000) Irritable bowel syndrome patients show altered sensitivity to exogenous opioids. Pain 87:137–147
Francis CY, Morris J, Whorwell PJ (1997) The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 11(2):395–402
Kellow JE, Phillips SF (1987) Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 92:1885–1893
Bueno L, Fioramonti J, Ruckebusch Y, Frexinos J, Coulom P (1980) Evaluation of colonic myoelectrical activity in health and functional disorders. Gut 21:480–485
Kellow JE, Delvaux M, Azpiroz F, Camilleri M, Quigley EM, Thompson DG (1999) Principles of applied neurogastroenterology: physiology/motility-sensation. Gut 45(Suppl 2):II17–II24
Farthing MJ (2004) Treatment options in irritable bowel syndrome. Best Pract Res Clin Gastroenterol 18:773–786
Mayer EA, Raybould HE (1990) Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology 99:1688–1704
Lasser RB, Bond JH, Levitt MD (1975) The role of intestinal gas in functional abdominal pain. N Engl J Med 293:524–526
Delvaux M, Louvel D, Lagier E, Scherrer B, Abitbol JL, Frexinos J (1999) The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 116:38–45
Corazziari E (1999) Role of opioid ligands in the irritable bowel syndrome. Can J Gastroenterol 13(Suppl A):71A–75A
Lavo B, Stenstam M, Nielsen AL (1987) Loperamide in treatment of irritable bowel syndrome—a double-blind placebo controlled study. Scand J Gastroenterol Suppl 130:77–80
Efskind PS, Bernklev T, Vatn MH (1996) A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 31:463–468
Hawkes ND, Rhodes J, Evans BK, Rhodes P, Hawthorne AB, Thomas GA (2002) Naloxone treatment for irritable bowel syndrome—a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther 16:1649–1654
Acknowledgment
This study was supported by Pain Therapeutics Inc.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kariv, R., Tiomny, E., Grenshpon, R. et al. Low-Dose Naltreoxone for the Treatment of Irritable Bowel Syndrome: A Pilot Study. Dig Dis Sci 51, 2128–2133 (2006). https://doi.org/10.1007/s10620-006-9289-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-006-9289-8